Bone Marrow Blast Percentage Calculator

Calculate blast % from a differential count for AML/MDS diagnosis

Convert raw blast, erythroid, and other nucleated cell counts from a 200- or 500-cell bone marrow differential into blast percentage of all nucleated cells and of non-erythroid cells, against the WHO 20% AML threshold. It runs free in your browser on Gera Tools, with nothing uploaded.

Last updated Source: Gera Tools

What is the WHO blast threshold for AML?

The WHO classification defines acute myeloid leukaemia as 20% or more blasts of all nucleated cells in the bone marrow or blood. Below 20% the picture usually falls into MDS or another category, subject to the clinical and genetic context.

The blast percentage in a bone marrow aspirate is the single number that most often decides whether a case is acute myeloid leukaemia. This calculator takes raw counts from your differential and returns the two denominators that matter — all nucleated cells and non-erythroid cells — against the WHO 20% threshold.

How it works

From the differential counts, the tool computes:

total_nucleated = blasts + erythroid + other
blast_%_total   = blasts / total_nucleated × 100
non_erythroid   = total_nucleated − erythroid
blast_%_NEC     = blasts / non_erythroid × 100      (when non_erythroid > 0)
erythroid_%     = erythroid / total_nucleated × 100

The percentage of all nucleated cells is the primary WHO denominator. When erythroid precursors reach 50% or more of the marrow, the percentage of non-erythroid cells (NEC) becomes relevant and the tool flags it.

Why two denominators exist

The “two denominator” approach comes from the different classification schemes that haematopathologists have used over the decades.

The WHO 2022 classification uses blast percentage of all nucleated marrow cells as the primary criterion. A blast count of 20% or more of all nucleated cells meets the diagnostic threshold for AML (with caveats for defining genetic abnormalities).

The FAB (French-American-British) classification — which preceded the WHO system — included an “M6b” erythroleukaemia category where blasts were counted as a percentage of non-erythroid cells in erythroid-rich marrows. Although the FAB system is no longer the primary classification, the NEC denominator still appears in some institutional protocols and is useful when erythroid hyperplasia would otherwise dilute the total-cell blast count significantly.

Worked example with erythroid expansion

A 500-cell differential from a marrow with heavy erythroid hyperplasia:

Cell typeCount
Blasts60
Erythroid precursors280
Other myeloid cells160
Total500
blast_%_total = 60 / 500 × 100 = 12%     (below WHO 20% threshold)
erythroid_%   = 280 / 500 × 100 = 56%    (≥50% → NEC denominator is relevant)
non_erythroid = 500 − 280 = 220
blast_%_NEC   = 60 / 220 × 100 = 27.3%  (above 20% on the NEC denominator)

This case would be below the WHO AML threshold on the primary denominator (12%) but above 20% on the NEC denominator (27.3%). The clinical, morphological, cytogenetic, and molecular context — including whether any AML-defining genetic lesion is present — determines classification. This calculator provides the arithmetic only.

Sampling error near the threshold

The 20% threshold is a bright line in the classification criteria, but blast counts near it carry real statistical uncertainty from sampling. A 200-cell count produces wider confidence intervals than a 500-cell count. For cases near 18–22%, a 500-cell differential is strongly preferred. Some centres perform counts on both an aspirate smear and a trephine imprint to improve reliability near the threshold.

This tool computes percentages only and does not provide diagnostic conclusions. All interpretation must be done in clinical context with morphology, flow cytometry, cytogenetics, and molecular results.